
FGI plans to introduce a paradigm shift in prenatal genomics by integrating advanced sequencing technologies with deep expertise across fetal, pediatric, clinical, and population genomics. FGI aims to move beyond limited prenatal testing using gene panels toward comprehensive clinical genomic screening.
FGI has developed a first-of-its-kind non-invasive fetal sequencing (NIFS) platform capable using maternal blood to screen ~23,000 fetal genes and identify clinically relevant genetic variation that may impact fetal and maternal health. We are establishing strategic international partnerships with leading commercial laboratories to expand the global delivery of NIFS technologies.
FGI will redefine prenatal care by engineering scalable and comprehensive non-invasive genomic technologies to deliver clinically relevant genetic information to patients.
FGI is not just improving tests — we’re transforming the future of maternal-fetal medicine with innovations built on validated technologies and data science, engineered with precision, and developed with deep expertise in real-world clinical implementation.
We are building the infrastructure for a new standard of prenatal care—one that replaces fragmented, narrow testing paradigms with scientifically rigorous, genome-scale precision medicine. Our goal is to responsibly translate decades of genomic expertise into information that drives meaningful improvements in maternal, fetal, newborn, and pediatric health.
Founded by scientific and clinical leaders, we are building the future rigorously and responsibly to improve clinical care.


Co-Founder
Director, Center for Genomic Medicine
Massachusetts General Hospital
Broad Institute of MIT and Harvard
Harvard Medical School

Co-Founder
Chief of Pediatrics
Boston Children’s Hospital
Harvard Medical School

Co-Founder
Director of Women’s Genetics
Columbia University Irving Medical Center

Our founders are lifelong healthcare providers and genomic medicine leaders who have pioneered the translation of genetics into clinical care for fetuses, newborns, children, and adults.
For over a decade, we have worked to move maternal–fetal genomic medicine beyond narrow panels and partial answers. While much of the current market promotes “expanded” care, many existing technologies evaluate only a small fraction of clinically reportable conditions accessible to genomics technologies. We started FGI to fundamentally change that trajectory.
FGI Operates at the intersection of biotechnology and healthcare delivery.
Copyright © 2026 First Genomic Insights - All Rights Reserved.